NCT06514976
Observational Study of Efficiency of Cytoflavin, in Patients With Ischemic Stroke Not Receiving Reperfusion Therapy
StatusRecruiting
PhaseNot specified
Primary completion (estimated)
At risk: Primary completion moved at least 1 year 8 months later.
See at-risk trials from POLYSAN Scientific & Technological Pharmaceutical Company
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Sep 30, 2025 to Jun 1, 2027 Show 4 more changesShow less
- Eligibility criteria expanded, about 14 words
- Trial status changed: Unknown → Recruiting
- Study completion pushed from Nov 1, 2025 to Aug 1, 2027
- Site details revised at 4 of 17 sites
- Minor Changed Registry marked status Unknown; last known: Recruiting
- Notable Primary completion date: Dec 30, 2024 to Sep 30, 2025
- Trial status: Recruiting to Unknown
- Study completion date: Mar 1, 2025 to Nov 1, 2025
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Percentage of patients with favorable functional outcome (score 0-2) according to Modified Rankin Scale (mRS) on Day of Discharge (assessment at Visit 4 or Visit 5, on Day of Discharge) and on Day 90;
Timeframe: Base, day 14, day 21, day 90
Secondary (6)
Total score according to Modified Rankin Scale (mRS) on Day of Discharge and Day 90 in the test and control group;
Total score according to Rivermead Scale on Day 7, Day 14, Day 21, and Day 90 in the test and control group
Change of the total score according to National Institute of Health Stroke Scale (NIHSS) on Day 3, Day 7, Day 14, and Day 21 as compared to the baseline level (Day 1);
Change of the total score according to Stroke-Specific Quality of Life Scale (SS-QOL) on Day 90 as compared to Day of Discharge;
Percentage of patients with repeated ACVA or TIA during the study;
Show 1 moreShow less
Percentage of patients with lethal outcome in the period of hospitalization and follow-up
Arms and interventions
The test group
Basic therapy + Cytoflavin
The control group
Basic therapy (with or without other neuroprotector)
Drugs: Cytoflavin
Sites
17 sites in 1 country